AgeX Therapeutics COO to depart as Juvenescence terminates services agreement; $3.9M debt

Serina Therapeutics, Inc.

Juvenescence notified AgeX it is terminating the agreement that provided Nafees Malik as COO; termination effective Dec 31, 2023.
Dr. Malik's engagement as COO of AgeX and its subsidiary Reverse Bioengineering ends December 27, 2023.
As of Nov 27, 2023, AgeX owed Juvenescence $3.9 million in secured loans and fees.
Juvenescence, AgeX's largest shareholder (79.4% of outstanding common shares), provided Dr. Malik's services at 85% cost.
No replacement for COO has been announced.

item 1.02 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Nafees Malik

Chief Operating Officer

SER · Serina Therapeutics, Inc.

Filed: December 1, 2023, 6:59 PM ET

In connection with the termination of the agreement pursuant to which Juvenescence has provided the services of our Chief Operating Officer, Nafees Malik, as set forth in

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Nafees Malik departed as Chief Operating Officer at Serina Therapeutics, Inc..

Role: Chief Operating Officer

Exact text from the filing

In connection with the termination of the agreement pursuant to which Juvenescence has provided the services of our Chief Operating Officer, Nafees Malik, as set forth in

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Serina Therapeutics, Inc. terminated Service Agreement with Juvenescence Limited for Dr. Nafees Malik with Juvenescence Limited valued at Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa (effective 2023-12-31).

Action: termination
Counterparty: Juvenescence Limited
Value: Termination of agreement for Dr. Malik's services; AgeX paid Juvenescence 85% of Dr. Malik's base sa
Effective: 2023-12-31

Exact text from the filing

On November 27, 2023, Juvenescence Limited (“Juvenescence”) notified AgeX that Juvenescence is terminating a March 29, 20219 the agreement that incorporated arrangements in effect since October 18, 2018 pursuant to which Juvenescence has provided AgeX with the services of Juvenescence’s employee Nafees Malik who served as Chief Operating Officer of AgeX and our subsidiary Reverse Bioengineering, Inc.

View on SEC.gov

245 material agreements filed in the last 30 days. Browse all material agreements →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-043393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.